

The prognostic significance of Ki67 before and after neo
cancer

Breast Cancer Research and Treatment

116, 53-68

DOI: [10.1007/s10549-008-0081-7](https://doi.org/10.1007/s10549-008-0081-7)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant/presurgical treatments. Breast Cancer Research, 2008, 10, S24.	2.2	2
2	Optimizing the implementation of future treatment using surrogate end-points. Breast Cancer Research, 2008, 10, S26.	2.2	5
3	A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Annals of Oncology, 2009, 20, 1193-1198.	0.6	70
5	Who would have thought a single Ki67 measurement would predict long-term outcome?. Breast Cancer Research, 2009, 11, S15.	2.2	18
6	Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer. Pharmacogenetics and Genomics, 2009, 19, 833-842.	0.7	13
7	Breast Cancer in the Personal Genomics Era. Current Genomics, 2010, 11, 146-161.	0.7	70
8	Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. Breast Cancer Research, 2010, 12, R39.	2.2	37
9	Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index. Supportive Care in Cancer, 2010, 18, 1553-1564.	1.0	18
10	Breast cancer, neoadjuvant chemotherapy and residual disease. Clinical and Translational Oncology, 2010, 12, 461-467.	1.2	17
11	Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Research and Treatment, 2010, 119, 315-323.	1.1	98
12	Differential subcellular expression of protein kinase C beta11 in breast cancer: correlation with breast cancer subtypes. Breast Cancer Research and Treatment, 2010, 124, 327-335.	1.1	16
13	Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2010, 122, 419-428.	1.1	45
14	The Use of Animal Models for Cancer Chemoprevention Drug Development. Seminars in Oncology, 2010, 37, 327-338.	0.8	49
15	Use of the Ki67 promoter to label cell cycle entry in living cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 564-570.	1.1	30
16	Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia. Leukemia Research, 2010, 34, 173-176.	0.4	11
17	Development of a bioassay to monitor circulating plasma Ki-67. Leukemia Research, 2010, 34, 848-849.	0.4	0
18	Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia. Leukemia Research, 2010, 34, 1320-1324.	0.4	15
20	Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. Clinical Medicine Insights: Oncology, 2010, 4, CMO.S4773.	0.6	109

#	ARTICLE	IF	CITATIONS
21	Comparative validation of the SP6 antibody to Ki67 in breast cancer. <i>Journal of Clinical Pathology</i> , 2010, 63, 800-804.	1.0	59
22	Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908. <i>Annals of Oncology</i> , 2010, 21, 707-716.	0.6	29
23	Neoadjuvant chemotherapy: are we barking up the right tree?. <i>Annals of Oncology</i> , 2010, 21, 675-679.	0.6	8
24	Prognostic Value of Estrogen Receptor and Ki-67 Index after Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Expressing High Levels of Proliferation at Diagnosis. <i>Oncology</i> , 2010, 79, 255-261.	0.9	26
25	Ki67 in breast cancer: prognostic and predictive potential. <i>Lancet Oncology</i> , The, 2010, 11, 174-183.	5.1	923
26	Designing adjuvant treatment based on biological measurements in the neoadjuvant setting. <i>Breast Cancer Research</i> , 2010, 12, S16.	2.2	2
27	Current and emerging biomarkers in breast cancer: prognosis and prediction. <i>Endocrine-Related Cancer</i> , 2010, 17, R245-R262.	1.6	380
28	Irradiation of normal mouse tissue increases the invasiveness of mammary cancer cells. <i>International Journal of Radiation Biology</i> , 2011, 87, 472-482.	1.0	23
29	Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1656-1664.	3.0	1,505
30	Clinical Implication of p53 Overexpression in Breast Cancer Patients Younger than 50 Years with a Triple-negative Subtype Who Undergo a Modified Radical Mastectomy. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 854-866.	0.6	25
32	Tailoring Therapy for Locally Advanced Breast Cancer Using Molecular Profiles. <i>Drugs</i> , 2011, 71, 1947-1955.	4.9	1
34	Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. <i>Breast Cancer Research</i> , 2011, 13, R22.	2.2	187
35	Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1301-1308.	1.2	32
36	Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies. <i>BMC Cancer</i> , 2011, 11, 341.	1.1	76
37	The anti-tumor effects of human immunodeficiency virus protease inhibitors: Ready for real time?. <i>International Journal of Cancer</i> , 2011, 128, 1-2.	2.3	2
38	Use of Dynamic Contrast-enhanced MR Imaging to Predict Survival in Patients with Primary Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Radiology</i> , 2011, 260, 68-78.	3.6	95
39	Prognostic Impact of Ki-67 Overexpression in Subgroups Categorized according to St. Gallen with Early Stage Breast Cancer. <i>Oncology</i> , 2011, 81, 345-352.	0.9	11
40	Nuclear NF- κ B/p65 expression and response to neoadjuvant chemotherapy in breast cancer. <i>Journal of Clinical Pathology</i> , 2011, 64, 130-135.	1.0	25

#	ARTICLE	IF	CITATIONS
41	Hormone Receptor Status Rather Than HER2 Status Is Significantly Associated With Increased Ki-67 and p53 Expression in Triple-Negative Breast Carcinomas, and High Expression of Ki-67 but Not p53 Is Significantly Associated With Axillary Nodal Metastasis in Triple-Negative and High-Grade Nonâ€“Triple-Negative Breast Carcinomas. <i>American Journal of Clinical Pathology</i> , 2011, 135, 230-237.	0.4	29
42	Biomarkers Predicting Clinical Benefit: Fact or Fiction?. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 63-66.	0.9	6
43	Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration. <i>PLoS Medicine</i> , 2012, 9, e1001216.	3.9	650
46	Ki-67 Index Guided Selection of Preoperative Chemotherapy for HER2-positive Breast Cancer: A Randomized Phase II Trial. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 1211-1214.	0.6	8
47	Marqueurs pronostiques et prÃ©dictifs des cancers du sein prÃ©coces. , 2012, , 41-49.		0
48	Proteomic Classification of Breast Cancer. <i>Current Drug Targets</i> , 2012, 13, 1495-1509.	1.0	16
49	A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. <i>Lancet Oncology</i> , The, 2012, 13, e240-e248.	5.1	64
50	MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression. <i>Breast Cancer Research</i> , 2012, 14, 324.	2.2	13
51	Prognostic Value of a Positive-to-negative Change in Hormone Receptor Status after Neoadjuvant Chemotherapy in Patients with Hormone Receptorâ€“positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 3002-3011.	0.7	44
52	Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. <i>BMC Medicine</i> , 2012, 10, 51.	2.3	297
53	Pathology Considerations in Patients Treated with Neoadjuvant Chemotherapy. <i>Surgical Pathology Clinics</i> , 2012, 5, 749-774.	0.7	14
54	Biomarkers in the diagnosis of primary and recurrent breast cancer. <i>Biomarkers in Medicine</i> , 2012, 6, 567-585.	0.6	25
55	Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients. <i>Medical Oncology</i> , 2012, 29, 3222-3231.	1.2	19
57	Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. <i>EJNMMI Research</i> , 2012, 2, 34.	1.1	27
58	A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracyclineâ€“containing neoadjuvant chemotherapy for breast cancer. <i>Journal of Surgical Oncology</i> , 2012, 105, 577-585.	0.8	17
59	Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. <i>Nature Medicine</i> , 2012, 18, 1052-1059.	15.2	219
60	Treatment Response to Preoperative Anthracycline-Based Chemotherapy in Locally Advanced Breast Cancer: The Relevance of Proliferation and Apoptosis Rates. <i>Pathology and Oncology Research</i> , 2013, 19, 577-588.	0.9	8
61	Classic â€œbroken cellâ€“techniques and newer live cell methods for cell cycle assessment. <i>American Journal of Physiology - Cell Physiology</i> , 2013, 304, C927-C938.	2.1	20

#	ARTICLE	IF	CITATIONS
62	Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 899-908.	1.1	23
65	Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. <i>World Journal of Surgical Oncology</i> , 2013, 11, 307.	0.8	19
66	Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 203-212.	1.1	45
67	A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: Extension and analysis of a previously reported cohort of patients. <i>European Journal of Surgical Oncology</i> , 2013, 39, 1046-1052.	0.5	19
68	Identification of intermediate risk breast cancer patients with 1-3 positive lymph nodes and excellent survival after tamoxifen as only systemic adjuvant therapy by use of markers of proliferation and apoptosis. <i>Breast</i> , 2013, 22, 643-649.	0.9	3
69	Biomarkers for the clinical management of breast cancer: International perspective. <i>International Journal of Cancer</i> , 2013, 133, 1-13.	2.3	144
70	The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with NO/N1 primary breast cancer. <i>SpringerPlus</i> , 2013, 2, 111.	1.2	12
71	Novel Methods and Tracers for Breast Cancer Imaging. <i>Seminars in Nuclear Medicine</i> , 2013, 43, 324-329.	2.5	52
72	Mitotic counts in breast cancer after neoadjuvant systemic chemotherapy and development of metastatic disease. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 91-97.	1.1	19
73	Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes. <i>International Journal of Clinical Oncology</i> , 2013, 18, 343-349.	1.0	12
75	Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow. <i>Molecular and Clinical Oncology</i> , 2013, 1, 1049-1054.	0.4	18
76	Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4521-4531.	3.2	137
77	Interobserver concordance of Ki67 labeling index in breast cancer: a pan breast cancer research group Ki67 research study. <i>Cancer Science</i> , 2013, 104, 1539-1543.	1.7	65
78	Prognostic Value of the Nodal Ratio and Ki-67 Expression in Breast Cancer Patients Treated with Postmastectomy Radiotherapy. <i>Journal of Breast Cancer</i> , 2013, 16, 274.	0.8	4
79	Neoadjuvant Chemotherapy with FOLFOX4 Regimen to Treat Advanced Gastric Cancer Improves Survival without Increasing Adverse Events: A Retrospective Cohort Study from a Chinese Center. <i>Scientific World Journal</i> , The, 2014, 2014, 1-10.	0.8	12
80	Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer. <i>British Journal of Cancer</i> , 2014, 110, 2847-2854.	2.9	35
81	Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting. <i>Tumor Biology</i> , 2014, 35, 9823-9830.	0.8	52
82	Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information. <i>Clinical Medicine Insights: Oncology</i> , 2014, 8, CMO.S18006.	0.6	111

#	ARTICLE	IF	CITATIONS
83	Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets. <i>Cancer Discovery</i> , 2014, 4, 232-245.	7.7	413
84	Ki-67 Proliferative Index in Gastroenteropancreatic Neuroendocrine Neoplasms. , 2014, 19, 256-260.		0
85	Omics Approaches in Breast Cancer. , 2014, , .		10
86	Breast Cancer Genomics. , 2014, , 53-103.		0
87	Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer. <i>Human Pathology</i> , 2014, 45, 249-258.	1.1	22
88	Lymph Node Counts and Ratio in Axillary Dissections Following Neoadjuvant Chemotherapy for Breast Cancer: A Better Alternative to Traditional pN Staging. <i>Annals of Surgical Oncology</i> , 2014, 21, 42-50.	0.7	12
89	Benefit from anthracyclines in relation to biological profiles in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 307-318.	1.1	18
92	New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity. <i>Clinical Cancer Research</i> , 2014, 20, 782-790.	3.2	242
93	Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 95-102.	1.1	35
94	Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. <i>Breast Cancer Research</i> , 2015, 17, 73.	2.2	55
95	Prognostic Significance of Ki67 Expression in Malignant Peritoneal Mesothelioma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 388-394.	0.6	25
96	Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients. <i>PLoS ONE</i> , 2015, 10, e0128368.	1.1	58
97	Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. <i>Oncologist</i> , 2015, 20, 1001-1010.	1.9	85
98	Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2015, 26, 75-80.	0.6	95
100	Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. <i>Modern Pathology</i> , 2015, 28, 1185-1201.	2.9	205
101	A standardized method for quantifying proliferation by Ki-67 and cyclin A immunohistochemistry in breast cancer. <i>Annals of Diagnostic Pathology</i> , 2015, 19, 243-248.	0.6	17
102	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. <i>Annals of Oncology</i> , 2015, 26, 1280-1291.	0.6	177
103	Abnormal expression of the Notch and Wnt/ β -catenin signaling pathways in stem-like ALDH ^{hi} CD44 ⁺ cells correlates highly with Ki-67 expression in breast cancer. <i>Oncology Letters</i> , 2015, 9, 1600-1606.	0.8	23

#	ARTICLE	IF	CITATIONS
104	EPMA position paper in cancer: current overview and future perspectives. EPMA Journal, 2015, 6, 9.	3.3	86
105	Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer. Clinical Breast Cancer, 2015, 15, 259-265.	1.1	34
106	Landscape of Neoadjuvant Therapy for Breast Cancer. Annals of Surgical Oncology, 2015, 22, 1408-1415.	0.7	47
107	Early Surrogate Markers of Treatment Activity: Where Are We Now?. Journal of the National Cancer Institute Monographs, 2015, 2015, 24-28.	0.9	15
108	Neoadjuvant Breast Cancer Trials: Translational Research in Drug Development. Current Breast Cancer Reports, 2015, 7, 151-160.	0.5	0
109	Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy. Annals of Oncology, 2015, 26, 307-313.	0.6	43
110	Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Breast Cancer, 2015, 22, 185-191.	1.3	77
111	FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer. Breast Cancer, 2015, 22, 308-316.	1.3	16
112	Neoadjuvant chemotherapy in breast cancers. Women's Health, 2016, 12, 480-491.	0.7	72
113	Personalized Treatment of Breast Cancer. , 2016, , .		2
114	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nature Reviews Clinical Oncology, 2016, 13, 674-690.	12.5	1,938
115	A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer. BMC Cancer, 2016, 16, 745.	1.1	14
116	Exploring circulating microRNA in the neoadjuvant treatment of breast cancer. International Journal of Cancer, 2016, 139, 12-22.	2.3	40
117	Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin. Scientific Reports, 2016, 6, 30091.	1.6	18
118	A meta-analysis of biomarkers for the prognosis of triple-negative breast cancer patients. Biomarkers in Medicine, 2016, 10, 771-790.	0.6	10
119	Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers. International Journal of Clinical Oncology, 2016, 21, 254-261.	1.0	19
120	Biomarkers of residual disease after neoadjuvant therapy for breast cancer. Nature Reviews Clinical Oncology, 2016, 13, 487-503.	12.5	43
121	Tumor Evolution Inferred by Patterns of microRNA Expression through the Course of Disease, Therapy, and Recurrence in Breast Cancer. Clinical Cancer Research, 2016, 22, 3651-3662.	3.2	6

#	ARTICLE	IF	CITATIONS
122	Strong cytoplasmic expression of NF- κ B/p65 correlates with a good prognosis in patients with triple-negative breast cancer. <i>Surgery Today</i> , 2016, 46, 843-851.	0.7	6
123	High Ki67 expression is an independent good prognostic marker in colorectal cancer. <i>Journal of Clinical Pathology</i> , 2016, 69, 209-214.	1.0	114
124	Dynamic contrast-enhanced and diffusion-weighted MRI of estrogen receptor-positive invasive breast cancers: Associations between quantitative MR parameters and Ki-67 proliferation status. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 94-102.	1.9	52
125	Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis. <i>Future Oncology</i> , 2017, 13, 1021-1034.	1.1	36
126	Ki67 assessment in breast cancer: an update. <i>Pathology</i> , 2017, 49, 166-171.	0.3	157
127	Neoadjuvant therapy in microsatellite-stable colorectal carcinoma induces concomitant loss of MSH6 and Ki-67 expression. <i>Human Pathology</i> , 2017, 63, 33-39.	1.1	22
128	Differences in Ki67 expressions between pre- and post-neoadjuvant chemotherapy specimens might predict early recurrence of breast cancer. <i>Human Pathology</i> , 2017, 63, 40-45.	1.1	32
129	Molecular Imaging and Precision Medicine in Breast Cancer. <i>PET Clinics</i> , 2017, 12, 39-51.	1.5	16
130	Ki-67 Expression by Immunohistochemistry and Quantitative Real-Time Polymerase Chain Reaction as Predictor of Clinical Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. <i>Journal of Oncology</i> , 2017, 2017, 1-8.	0.6	29
131	Pre-operative Endocrine Therapy. <i>Current Breast Cancer Reports</i> , 2017, 9, 202-209.	0.5	17
132	PROGNOSTIC BIOMARKERS IN TRIPLE NEGATIVE BREAST CANCER AS A POTENTIAL TARGET FOR FUTURE DRUG DISCOVERY. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2017, 10, 24.	0.3	0
133	Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy. <i>Oncologist</i> , 2018, 23, 670-678.	1.9	50
134	Optimizing Adjuvant and Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. , 2018, , 83-94.		3
135	Triple-Negative Breast Cancer. , 2018, , .		0
136	Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. <i>Clinical Cancer Research</i> , 2018, 24, 3079-3086.	3.2	15
137	Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy. <i>Future Oncology</i> , 2018, 14, 849-859.	1.1	14
138	Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , 2018, 4, 946-953.	1.6	70
140	Effects of core needle biopsy and subsequent neoadjuvant chemotherapy on molecular alterations and outcome in breast cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 677-685.	1.0	9

#	ARTICLE	IF	CITATIONS
141	A Machine Learning Approach for the Association of ki-67 Scoring with Prognostic Factors. <i>Journal of Oncology</i> , 2018, 2018, 1-7.	0.6	3
142	How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. <i>ESMO Open</i> , 2018, 3, e000357.	2.0	112
143	Pathology assessment of pancreatic cancer following neoadjuvant treatment: Time to move on. <i>Pancreatology</i> , 2018, 18, 467-476.	0.5	57
144	Can We Hang Our Hats on One Percent?. <i>Oncologist</i> , 2018, 23, 642-644.	1.9	0
145	Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer. <i>Cancer Medicine</i> , 2018, 7, 4420-4433.	1.3	46
147	Breast specimen handling and reporting in the post-neoadjuvant setting: challenges and advances. <i>Journal of Clinical Pathology</i> , 2019, 72, 120-132.	1.0	20
148	Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 557-568.	1.1	10
149	Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591982771.	1.4	38
150	Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy. <i>Journal of Breast Cancer</i> , 2019, 22, 497.	0.8	20
151	Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e030502.	0.8	15
152	Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 2180.	1.0	12
153	Association Between Shear Wave Elastography of Virtual Touch Tissue Imaging Quantification Parameters and the Ki-67 Proliferation Status in Luminal Type Breast Cancer. <i>Journal of Ultrasound in Medicine</i> , 2019, 38, 73-80.	0.8	7
154	Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab. <i>Oncology</i> , 2020, 98, 35-41.	0.9	4
155	Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 105-111.	1.1	13
156	Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer. <i>Oncologist</i> , 2020, 25, e1355-e1362.	1.9	8
157	Update on Quantitative Imaging for Predicting and Assessing Response in Oncology. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 505-517.	2.5	2
158	Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors. <i>Cancers</i> , 2020, 12, 2012.	1.7	13
159	Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative Ki67 measurement in breast cancer. <i>Breast</i> , 2020, 53, 102-110.	0.9	8

#	ARTICLE	IF	CITATIONS
160	Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience. <i>Diagnostics</i> , 2020, 10, 573.	1.3	13
161	A comparative study between Ki67 positive versus Ki67 negative females with breast cancer: Cross sectional study. <i>Annals of Medicine and Surgery</i> , 2020, 60, 232-235.	0.5	5
162	Influences of preoperative metformin on immunological factors in early breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 55-63.	1.1	12
163	Clinical Application of Image Analysis in Pathology. <i>Advances in Anatomic Pathology</i> , 2020, 27, 227-235.	2.4	19
164	Early stage triple negative breast cancer: Management and future directions. <i>Seminars in Oncology</i> , 2020, 47, 201-208.	0.8	23
165	Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome. <i>Clinical Cancer Research</i> , 2020, 26, 1977-1984.	3.2	9
166	Combining Adjuvant Radiotherapy With Capecitabine in Chemotherapy-resistant Breast Cancer: Feasibility, Safety, and Toxicity. <i>Clinical Breast Cancer</i> , 2020, 20, 344-352.e1.	1.1	11
167	Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study. <i>British Journal of Cancer</i> , 2020, 122, 1747-1753.	2.9	7
168	Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience. <i>Cancers</i> , 2020, 12, 941.	1.7	38
169	Evaluation of the Effect of <i>Foeniculum vulgare</i> on the Expression of E-Cadherin, Dysadherin and Ki-67 in BALB/C Mice with 4T1 Model of Breast Cancer. <i>Nutrition and Cancer</i> , 2021, 73, 318-328.	0.9	4
170	Effect of Toremifene on Endometrium and Neurocognitive Function in Patients with Breast Cancer Based on Resting-State Functional Magnetic Resonance Imaging. <i>World Neurosurgery</i> , 2021, 149, 436-443.	0.7	2
171	KI-67 LI Expression in Triple-Negative Breast Cancer Patients and Its Significance. <i>Breast Cancer: Basic and Clinical Research</i> , 2021, 15, 117822342110169.	0.6	10
172	PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy. <i>Cancers</i> , 2021, 13, 746.	1.7	9
173	Correlation between semiquantitative and volumetric 18F-FDG PET/computed tomography parameters and Ki-67 expression in breast cancer. <i>Nuclear Medicine Communications</i> , 2021, 42, 656-664.	0.5	9
174	What shear wave elastography parameter best differentiates breast cancer and predicts its histologic aggressiveness?. <i>Ultrasonography</i> , 2021, 40, 265-273.	1.0	14
175	Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study. <i>Annals of Translational Medicine</i> , 2021, 9, 707-707.	0.7	11
176	PathoNet introduced as a deep neural network backend for evaluation of Ki-67 and tumor-infiltrating lymphocytes in breast cancer. <i>Scientific Reports</i> , 2021, 11, 8489.	1.6	33
177	Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience. <i>Journal of Oncology</i> , 2021, 2021, 1-7.	0.6	10

#	ARTICLE	IF	CITATIONS
178	Neoadjuvant Chemotherapy for Breast Cancer: Moving Beyond Pathological Complete Response in the Molecular Age. <i>Acta Medica Academica</i> , 2021, 50, 88.	0.3	8
179	Differences in tumour heterogeneity based on dynamic contrast-enhanced MRI between tumour and peritumoural stroma for predicting Ki-67 status of invasive ductal carcinoma. <i>Clinical Radiology</i> , 2021, 76, 470.e13-470.e22.	0.5	1
180	Prediction and assessment of response to neoadjuvant chemotherapy in breast cancer: The responsibilities of breast pathologists. <i>Breast Journal</i> , 2021, 27, 629-630.	0.4	1
181	Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 98, 102222.	3.4	21
182	Ribosome induces transdifferentiation of A549 and H-111-TC cancer cell lines. <i>Biochemistry and Biophysics Reports</i> , 2021, 26, 100946.	0.7	4
183	Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. <i>Cancers</i> , 2021, 13, 4455.	1.7	73
184	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2021, 113, 808-819.	3.0	319
185	GSTP1 DNA Methylation and Expression Status Is Indicative of 5-aza-2-Deoxycytidine Efficacy in Human Prostate Cancer Cells. <i>PLoS ONE</i> , 2011, 6, e25634.	1.1	49
186	Response Prediction to Neoadjuvant Chemotherapy: Comparison between Pre-Therapeutic Gene Expression Profiles and In Vitro Chemosensitivity Assay. <i>PLoS ONE</i> , 2013, 8, e66573.	1.1	7
188	Acetylation-mediated degradation of HSD17B4 regulates the progression of prostate cancer. <i>Aging</i> , 2020, 12, 14699-14717.	1.4	16
189	The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 76974-76986.	0.8	34
190	Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy. <i>Oncotarget</i> , 2017, 8, 86423-86434.	0.8	14
191	Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy. <i>Oncotarget</i> , 2015, 6, 18174-18182.	0.8	21
192	Decrease in the Ki67 index during neoadjuvant chemotherapy predicts favorable relapse-free survival in patients with locally advanced breast cancer. <i>Cancer Biology and Medicine</i> , 2019, 16, 575-586.	1.4	14
193	Prognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014. <i>Iranian Journal of Pathology</i> , 2018, 13, 71-77.	0.2	5
194	Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population. <i>South Asian Journal of Cancer</i> , 2016, 05, 196-203.	0.2	3
195	Study of Ki-67 index in the molecular subtypes of breast cancer: Inter-observer variability and automated scoring. <i>Indian Journal of Cancer</i> , 2020, 57, 289-295.	0.2	2
196	Overexpression of HER-2/neu in Malignant Mammary Tumors: Translation of Clinicopathological Features from Dog to Human. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 6415-6421.	0.5	28

#	ARTICLE	IF	CITATIONS
197	Higher Ki67 Expression is Associates With Unfavorable Prognostic Factors and Shorter Survival in Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 1381-1385.	0.5	32
199	Response prediction to neoadjuvant chemotherapy: Comparison between pretherapeutic gene expression profiles and in vitro chemosensitivity assay.. Journal of Clinical Oncology, 2010, 28, 10516-10516.	0.8	0
200	Significance of Ki-67 Expression and Risk Category (St. Gallen 2007) in Elderly Breast Cancer Patients, with Emphasis on the Need for Postoperative Adjuvant Therapy. The Showa University Journal of Medical Sciences, 2011, 23, 153-164.	0.1	0
201	- Spliceomics: The OMICS of RNA Splicing. , 2013, , 224-247.		0
202	Systemic Therapy. , 2014, , 381-420.		0
203	The peculiarities of surgical service of locally advanced breast cancer after neoadjuvant systemic treatment. UÅenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova, 2015, 22, 42-47.	0.0	0
204	Inflammatory and Locally Advanced Breast Cancer. , 2016, , 411-435.		0
205	Essence of Neoadjuvant Therapy. , 2016, , 235-246.		0
206	Proliferation Markers in Breast Cancer. , 2016, , 81-98.		0
207	Reliability of Core Needle Biopsy in Evaluating Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2, and Ki-67 Status. Journal of Breast Disease, 2016, 4, 70-76.	0.2	0
210	Bilateral Triple Negative Invasive Ductal Breast Carcinoma in a <i>BRCA1</i> Mutation Carrier with Discrepant Pathologic Response to Neoadjuvant Chemotherapy. Journal of the Korean Society of Radiology, 2020, 81, 428.	0.1	0
211	Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. International Journal of Clinical and Experimental Pathology, 2014, 7, 6862-70.	0.5	22
212	Prognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014. Iranian Journal of Pathology, 2018, 13, 71-77.	0.2	3
213	Biomarkers Changes after Neoadjuvant Chemotherapy in Breast Cancer: A Seven-Year Single Institution Experience. Diagnostics, 2021, 11, 2249.	1.3	7
214	Pathology after neoadjuvant treatment â€“ How to assess residual disease. Breast, 2022, 62, S25-S28.	0.9	18
215	Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy. Scientific Reports, 2022, 12, 91.	1.6	13
216	Giant parathyroid tumours in primary hyperparathyroidism: a systematic review. Langenbeck's Archives of Surgery, 2022, 407, 501-516.	0.8	5
217	Stroma composition and proliferative activity are related to therapy response in neoadjuvant treated pancreatic ductal adenocarcinoma. Histology and Histopathology, 2021, 36, 733-742.	0.5	5

#	ARTICLE	IF	CITATIONS
218	Trichoderma longibrachiatum-Associated Skin Inflammation and Atypical Hyperplasia in Mouse. <i>Frontiers in Medicine</i> , 2022, 9, 865722.	1.2	0
219	A hierarchical approach to combine histological grade and immunohistochemical factors to identify high-risk luminal breast cancers. <i>Ecancermedalscience</i> , 0, 16, .	0.6	0
221	External verification and improvement of the Neo-Bioscore staging system in a Chinese cohort. <i>Annals of Translational Medicine</i> , 2022, 10, 626-626.	0.7	1
222	Postneoadjuvant treatment for triple-negative breast cancer. <i>Current Opinion in Oncology</i> , 2022, 34, 623-634.	1.1	3
223	The cyclin dependent kinase inhibitor p21Cip1/Waf1 is a therapeutic target in high-risk neuroblastoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
227	Radiomics of dynamic contrast-enhanced magnetic resonance imaging parametric maps and apparent diffusion coefficient maps to predict Ki-67 status in breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
228	Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
229	Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 67-86.	1.1	2
230	Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
231	The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations. <i>Cancers</i> , 2023, 15, 808.	1.7	8
232	Beneficial Proapoptotic Effect of Heterobasidion Annosum Extract in Colorectal Cancer Xenograft Mouse Model. <i>Molecules</i> , 2023, 28, 1352.	1.7	1
233	The Survival of Patients with Triple Negative Breast Cancer Undergoing Chemotherapy Along with Lifestyle Change Interventions. <i>Archives of Breast Cancer</i> , 2023, 10, 66-73.	0.0	1
234	Prognostic analysis of three forms of Ki-67 in patients with breast cancer with non-pathological complete response before and after neoadjuvant systemic treatment. <i>Cancer Medicine</i> , 2023, 12, 9363-9372.	1.3	4
235	The Utility of Quantitative Parameters of Shear-Wave Elastography to Predict Prognostic Histologic Features of Breast Cancer. <i>Ultrasound Quarterly</i> , 2023, 39, 81-85.	0.3	0
236	Intratumoral heterogeneity, treatment response, and survival outcome of ER-positive HER2-positive breast cancer. <i>Cancer Medicine</i> , 0, , .	1.3	1
237	Synthetic Dataset Generation From Histopathology Images For Quantizing Necrosis In Post Neo-Adjuvant Chemotherapy Resection Specimen. , 2023, , .		0